AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today announces a summary of its major accomplishments over the past two years. These milestones underscore meaningful clinical progress and regulatory validation across the Company’s lead drug candidates. Oncotelic’s pipeline includes multiple late-stage programs t ...

Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and clinical pipeline is supported by the innovations and intellectual property generated by Dr. Trieu AGOURA HILLS, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”), a clinical stage biopharmaceutical company developing transformative oncology and ...

Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and clinical pipeline is supported by the innovations and intellectual property generated by Dr. Trieu AGOURA HILLS, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”), a clinical stage biopharmaceutical company developing transformative oncology and ...

公司核心技术与领导层背景 - 公司专注于开发变革性肿瘤学和免疫疗法治疗药物 处于临床阶段[1] - 公司CEO Dr Vuong Trieu是行业先驱 拥有超过500项专利申请和75项授权专利 涵盖生物制剂 小分子 纳米颗粒和诊断领域[2] - Dr Trieu曾共同发明并开发Abraxane（纳米颗粒紫杉醇） 2010年被Celgene以29亿美元收购 2015年开发并出售Cynviloq（纳米颗粒紫杉醇）给NantPharma 交易价值13亿美元[2] 研发管线与知识产权布局 - 公司管线包括OT-101（TGF-β抑制剂）处于胰腺癌III期临床 另有ARDS/COVID-19适应症[7] - OXi4503（血管破坏剂）处于AML/MDS的II期临床 正向关键III期设计推进[7] - CA4P/Fosbretabulin为晚期肿瘤资产 正在重新定位 AL-101（鼻内阿扑吗啡）处于帕金森病和性功能障碍的II期临床[7] - AL-102（鞘内注射寡核苷酸反义药物）处于阿尔茨海默病的发现阶段 儿科罕见病项目针对孤儿适应症 可能产生优先审评券[7] - 公司拥有CEO Dr Trieu创造的超过150项专利申请和39项美国授权专利 知识产权组合构成公司战略基石[4][6] 业务模式与战略合作 - 公司通过合资企业许可和共同开发特定候选药物 目前拥有GMP Bio合资企业45%股权 该合资企业在Dr Trieu领导下推进自身管线 强化公司在肿瘤和罕见病治疗领域的战略地位[6] - 公司致力于将肿瘤微环境生物学转化为全球受保护的临床就绪技术 重新定义药物递送 监测和个性化治疗方式[5]